Cromolyn sodium in the treatment of asthma: its effectiveness and use.
Thirty-six asthmatic children received placebo and cromolyn sodium, a new drug, in a double-blind crossover study; the majority were not using corticosteroids. Significant decreases in wheezing, breathlessness at rest, and cough occurred when the active drug was compared to placebo. Marked preference for cromolyn over placebo was expressed at the end of the study. Our results agree with previous reports on the effectiveness of cromolyn sodium. We found this drug to be especially useful as an adjunct to other treatment in the control of asthmatic children.
D000281:Administration, Intranasal; D000284:Administration, Oral; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy*; D002648:Child; D019411:Clinical Laboratory Techniques; D002986:Clinical Trials as Topic; D004205:Cromolyn Sodium / Q000008:administration & dosage / Q000592:standards / Q000627:therapeutic use*; D004341:Drug Evaluation; D000939:Epitopes; D006801:Humans; D010349:Patient Compliance; D010919:Placebos
D000305:Adrenal Cortex Hormones; D000939:Epitopes; D010919:Placebos; D004205:Cromolyn Sodium